142nd APHA Annual Meeting and Exposition

Annual Meeting Recordings are now available for purchase

306346
EndTobacco - A Program Linking the WHO MPOWER Framework with the CDC Best Practices for Evidence-based Tobacco Control at Institutional, Local and National Levels

142nd APHA Annual Meeting and Exposition (November 15 - November 19, 2014): http://www.apha.org/events-and-meetings/annual
Tuesday, November 18, 2014 : 3:10 PM - 3:30 PM

Ernest Hawk, MD, MPH , Division of Cancer Prevention & Population Sciences, Univ of Texas MD Anderson Cancer Center, Houston, TX
Jennifer Tektiridis, PhD , Division of Cancer Prevention & Population Sciences, UT MD Anderson Cancer Center, Houston, TX
David W. Wetter, PhD , Department of Health Disparities Research, The University of Texas MD Anderson Cancer Center, Houston, TX
Lewis Foxhall, MD , Office of Health Policy, The University of Texas MD Anderson Cancer Center, Houston, TX
Jo Ann Ward, MPH , Public Affairs and Public Education Office, UT MD Anderson Cancer Center, Houston, TX
Mark Moreno , Governmental Relations, UT MD Anderson Cancer Center, Houston, TX
Martha Salas , Division of Cancer Prevention, UT MD Anderson Cancer Center, Houston, TX
Despite advances in tobacco control and reductions in tobacco use, smoking remains a significant global public health concern, responsible for approximately 30% of all cancer deaths. Motivated by the daily suffering of patients and their families as witnessed by faculty and staff from across the institution, MD Anderson is making ending tobacco an institutional public health priority. Our goal is to end tobacco use and addiction among our patients, employees, and their families; and to lead, follow, and partner to achieve this goal at institutional, local/regional/state and national/international levels.

Over 20 MD Anderson scientists, clinicians, administrative leaders, and public health practitioners leveraged the World Health Organization’s MPOWER framework along with the Centers for Disease Control ‘s (CDC) Best Practices for Comprehensive Tobacco Control Programs to recommend evidence-based strategies and specific actions for addressing tobacco use in three areas: policy, education and clinical services, at three levels: within its own institution, local/state and national/international. This initiative calls for an unprecedented and sustained institutional commitment to leadership, investment, and collaboration to advance evidence-based tobacco control. The initiative is called “EndTobacco,” an inspirational and aspirational call to action, perfectly aligned with MD Anderson’s mission of Making Cancer History®.

Forging partnerships across a range of stakeholders is critical to achieving EndTobacco goals of reducing the prevalence of smoking, the proportion of non-smokers exposed to second-hand smoke and increasing cessation attempts by current smokers. A first step is to disseminate the framework, strategies and actions to others who may join with us to EndTobacco.

Learning Areas:

Program planning

Learning Objectives:
Explain how cancer centers can leverage their resources and expertise to develop a tobacco control plan at multiple levels: institutional, local/regional/state, and national/international. Discuss how to link the WHO MPOWER framework and CDC Best Practices in Cancer Control in a plan for tobacco control. List evidence-based tobacco control interventions within the context of the MPOWER framework at multiple levels.

Keyword(s): Tobacco Control

Presenting author's disclosure statement:

Qualified on the content I am responsible for because: In my role as a member of the Cancer Prevention & Control Platform Leadership Team, I co-led the planning and development of the EndTobacco Program at MD Anderson in collaboration with the over 20 faculty leaders in tobacco control and staff members of the EndTobacco Workgroup.
Any relevant financial relationships? No

I agree to comply with the American Public Health Association Conflict of Interest and Commercial Support Guidelines, and to disclose to the participants any off-label or experimental uses of a commercial product or service discussed in my presentation.